Comparison of Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab as the Primary Treatment of Clinically Significant Macular Edema

Liu, Qingyun; Hu, Yijun; Yu, Honghua; Yuan, Ling; Hu, Jie; Atik, Alp; Guan, Meng; Li, Dongli; Li, Xin; Tang, Shibo

doi:10.1097/iae.0000000000000300

Cited by 28 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, comparison of mean visual gains in the subgroup with serous macular detachment during the first year revealed no significant difference between groups 1, 2, and 3 (4.0, 6.0, and 6.0 letters, respectively, p = 0.342). This finding contradicts previous conceptions which favor intravitreal triamcinolone over intravitreal bevacizumab in eyes with serous retinal detachment in terms of visual benefit [16].…”

Section: Discussioncontrasting

confidence: 56%

Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema

2017

View full text Add to dashboard Cite

Objective: To compare the visual and anatomical outcomes of intravitreal ranibizumab (group 1), bevacizumab (group 2), and triamcinolone (group 3) for center-involving diabetic macular edema. Methods: We retrospectively enrolled 275 eyes of 208 consecutive patients. Visual acuity (VA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters and central macular thickness (CMT) values on optical coherence tomography were extracted. Reported side effects were noted. Results: At 6 months, the mean changes in VA in group 1, group 2, and group 3 were +4.9, +4.3, and +4.6 letters, respectively (p = 0.911). Improvement of CMT at 6 and 24 months was significantly better in group 3 compared to groups 1 and 2 (p = 0.012 and p = 0.001, respectively). At 24 months, the only independent variable affecting the change in VA was initial VA (p = 0.020). Cataract and glaucoma prevalences were higher in group 3 (p = 0.000 and p = 0.001, respectively). Conclusions: Three treatment methods had similar effects with regard to improvement in VA; however, intravitreal triamcinolone provided additional anatomical improvement.

show abstract

Section: Discussioncontrasting

confidence: 56%

Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema

2017

View full text Add to dashboard Cite

show abstract

“…Recent studies have even shown that IVTA has a positive effect on those forms of DME that are refractory to Retinal laser treatment [17]. Various studies including that of Masahiko Shimura et al; [18] Liu Q1 et al; [19] etc. demonstrated that Triamcinolone acetonide is more efficient is reducing DME and provided better and longer lasting visual improvement relative to Bevacizumab.…”

Section: Discussionmentioning

confidence: 99%

Clinical Evaluation of Intravitreal Triamcinolone Acetonide in Diabetic Macular Oedema

Ahmed¹,

Puzari²,

Sarkar³

2016

SJAMS

View full text Add to dashboard Cite

The study was carried out to evaluate prospectively the efficacy and safety of intravitreal Triamcinolone acetonide (IVTA) injection in Diabetic Macular Oedema (DME). Patient who were diagnosed to have DME were enrolled in the study after obtaining written informed consent and fulfilling the inclusion criteria. They were then subjected to comprehensive eye examination followed by recording of best corrected visual acuity (BCVA) with Snellen chart and obtaining coloured fundus photography and fundus Fluorescein Angiography (FFA) before treatment. Triamcinolone was injected in each eye of Test group. BCVA assessment, coloured fundus photo recording and FFA were performed at 1 st and 3 rd post IVTA month's follow up visit. Intraocular pressure (10P) was measured at every follow up. 100 eyes of 90 patients were selected. 50 eyes randomized to receive active treatment (Test Group) and rest 50 eyes of another 50 patients were put on to strict metabolic control (Control Group) Significant improvement was noticed in visual acuity, in coloured fundus picture and also in FFA in test eye group both at 1 month and at 3 months follow up. 10P rise was seen in only 10% of test eyes. This IVTA is a premising, effective and relatively safe therapeutic mode of treatment for DME and it was observed to have definite potential in improving visual acuity in short terms. The side effects are also transient. Further ongoing work on IVTA would pave the way for finding more effective regime for managing DME.

show abstract

“…Triamcinolone acetonide is a hydrophobic small molecule drug. Its suspension is commercially available and has been used as a sustained release formulation through intravitreal or subtenon injection to treat various chorioretinal disorders [33][34][35]. TA has been evaluated with suprachoroidal injection and Olsen et al reported that TA remained in the local ocular tissue for at least 120 days following a 12 μL TA suspension suprachoroidal cannulation [10].…”

Section: Discussionmentioning

confidence: 98%

Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model

Chen

Liu

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

Comparison of Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab as the Primary Treatment of Clinically Significant Macular Edema

Cited by 28 publications

References 30 publications

Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema

Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema

Clinical Evaluation of Intravitreal Triamcinolone Acetonide in Diabetic Macular Oedema

Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model

Contact Info

Product

Resources

About